Aixirefu Aikebaier, Chen Rong, Wang Hong
Department of Orthopeadics, Ya'an Traditional Chinese Medicine Hospital Ya'an 625000, Sichuan, China.
Am J Transl Res. 2024 Sep 15;16(9):4256-4267. doi: 10.62347/JUJV3321. eCollection 2024.
Intra-articular administration of mesenchymal stem cells (MSCs) presents a novel methodology for managing osteoarthritis, but there is still no definite evidence of its efficacy.
To assess the comparative effectiveness of MSCs and platelet-rich plasma (PRP) for managing osteoarthritis by reviewing the literature and using meta-analysis.
Randomized controlled trials and cohort studies comparing MSCs and PRP for managing osteoarthritis were included. We searched 'osteoarthritis', 'mesenchymal stem cell', 'platelet-rich plasma', and other words in Pubmed, Embase, and Cochrane Library database. The search period encompassed the entire duration of the databases, starting from its inception until April 2024. Two researchers conducted the literature search, extracting data, and evaluating quality as distinct processes. Meta-analysis was carried out using the software RevMan5.3, and the calculation of weighted mean difference (WMD) and 95% confidence interval (CI) were performed using either a fixed-effect model or a random-effects model.
Eleven studies were included, comprising 8 randomized controlled trials and 3 cohort studies. A total of 693 individuals participated in the study, of which 394 received intra-articular injections of MSCs (group A) and 299 received intra-articular injections of PRP (group B). The two groups were comparable in the five dimensions of knee injury and osteoarthritis outcome score (KOOS) [pain (WMD: 0.38, 95% CI: -3.62 to 4.38, > 0.05), symptoms (WMD: -1.48, 95% CI: -5.90 to 2.94, > 0.05), activities of daily living (ADL, WMD: -2.36, 95% CI: -6.87 to 2.14, > 0.05), function in sport and recreation (Sport/Rec, WMD: -3.84, 95% CI: -10.60 to 2.92, > 0.05), knee-related quality of life (QOL, WMD: 0.09, 95% CI: -5.48 to 5.67, > 0.05)] and Western Ontario and McMaster Universities osteoarthritis index (WOMAC, WMD: 0.47, 95% CI: -3.76 to 4.70, > 0.05). Compared with group A, the International Knee Documentation Committee Subjective Knee Form (IKDC, WMD: 4.19, 95% CI: 2.57 to 5.82, < 0.001) score of group B was higher.
The short-term effectiveness of intra-articular administration of PRP for managing osteoarthritis is slightly better than that of MSCs. However, because of the limited quantity of incorporated research studies and the potential for bias, requisite in the future are studies of substantial size and superior quality.
关节腔内注射间充质干细胞(MSCs)是治疗骨关节炎的一种新方法,但目前仍缺乏其疗效的确切证据。
通过文献回顾和荟萃分析,评估间充质干细胞和富血小板血浆(PRP)治疗骨关节炎的相对疗效。
纳入比较间充质干细胞和富血小板血浆治疗骨关节炎的随机对照试验和队列研究。我们在PubMed、Embase和Cochrane图书馆数据库中检索了“骨关节炎”、“间充质干细胞”、“富血小板血浆”等关键词。检索时间涵盖数据库的整个存续期,从创建到2024年4月。两名研究人员分别进行文献检索、数据提取和质量评估。使用RevMan5.3软件进行荟萃分析,采用固定效应模型或随机效应模型计算加权平均差(WMD)和95%置信区间(CI)。
共纳入11项研究,包括8项随机对照试验和3项队列研究。共有693名个体参与研究,其中394人接受关节腔内注射间充质干细胞(A组),299人接受关节腔内注射富血小板血浆(B组)。两组在膝关节损伤和骨关节炎疗效评分(KOOS)的五个维度[疼痛(WMD:0.38,95%CI:-3.62至4.38,P>0.05)、症状(WMD:-1.48,95%CI:-5.90至2.94,P>0.05)、日常生活活动(ADL,WMD:-2.36,95%CI:-6.87至2.14,P>0.05)、运动和娱乐功能(Sport/Rec,WMD:-3.84,95%CI:-10.60至2.92,P>0.05)、膝关节相关生活质量(QOL,WMD:0.09,95%CI:-5.48至5.67,P>0.05)]以及西安大略和麦克马斯特大学骨关节炎指数(WOMAC,WMD:0.47,95%CI:-3.76至4.70,P>0.05)方面具有可比性。与A组相比,B组的国际膝关节文献委员会主观膝关节评分表(IKDC,WMD:4.19,95%CI:2.57至5.82,P<0.001)得分更高。
关节腔内注射富血小板血浆治疗骨关节炎的短期疗效略优于间充质干细胞。然而,由于纳入研究数量有限且存在偏倚可能性,未来需要开展大规模、高质量的研究。